Latest Ratios: P/E Ratio 20.0x · EV/EBITDA 15.3x · ROE 35.5%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $14.1B | $12.3B | $10.1B | $7.7B | $5.2B | $5.9B | $6.4B | $5.6B | $6.2B | $9.5B | $3.7B |
| Enterprise Value | $13.8B | $12.0B | $10.0B | $7.6B | $4.9B | $5.3B | $6.1B | $5.3B | $5.9B | $9.3B | $3.8B |
| P/E Ratio → | 19.97 | 15.68 | 19.30 | 36.91 | 28.64 | 25.39 | 57.34 | 17.27 | 8.90 | 62.04 | — |
| P/S Ratio | 6.08 | 5.29 | 4.64 | 4.21 | 3.23 | 4.11 | 6.46 | 5.74 | 7.21 | 20.96 | 19.51 |
| P/B Ratio | 7.24 | 5.68 | 4.48 | 3.41 | 2.09 | 2.67 | 3.40 | 3.29 | 4.78 | 33.28 | 41.82 |
| P/FCF | 16.71 | 14.55 | 15.87 | 45.27 | 23.22 | 17.51 | 35.73 | 10.80 | 16.09 | 65.65 | 18.26 |
| P/OCF | 15.95 | 13.89 | 14.37 | 23.14 | 14.36 | 14.70 | 30.54 | 10.53 | 14.80 | 57.27 | 18.11 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.16 | 4.63 | 4.17 | 3.04 | 3.69 | 6.19 | 5.51 | 6.85 | 20.59 | 19.71 |
| EV / EBITDA | 15.31 | 13.29 | 15.84 | 38.85 | 22.01 | 17.64 | 51.28 | 14.02 | 13.19 | 55.75 | — |
| EV / EBIT | 15.82 | 13.41 | 14.54 | 44.70 | 24.29 | 18.48 | 55.53 | 13.40 | 13.34 | 55.75 | — |
| EV / FCF | — | 14.18 | 15.83 | 44.84 | 21.84 | 15.74 | 34.22 | 10.38 | 15.30 | 64.49 | 18.44 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.4% | 96.4% | 96.5% | 96.0% | 96.4% | 96.3% | 96.3% | 96.6% | 96.9% | 96.7% | 96.6% |
| Operating Margin | 37.6% | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% | 11.1% | 38.2% | 51.4% | 36.7% | -14.7% |
| Net Profit Margin | 33.7% | 33.7% | 24.0% | 11.4% | 11.3% | 16.1% | 11.3% | 33.2% | 80.8% | 34.1% | -36.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 35.5% | 35.5% | 23.1% | 8.7% | 7.8% | 11.3% | 6.3% | 21.6% | 87.8% | 82.4% | -78.6% |
| ROA | 27.0% | 27.0% | 17.7% | 6.9% | 6.4% | 9.7% | 5.6% | 19.4% | 66.4% | 24.6% | -15.1% |
| ROIC | 32.1% | 32.1% | 20.6% | 5.9% | 8.0% | 13.3% | 5.4% | 22.5% | 59.6% | 102.4% | -16.1% |
| ROCE | 35.0% | 35.0% | 23.7% | 6.5% | 8.0% | 13.6% | 6.0% | 24.2% | 47.3% | 38.3% | -9.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.08 | 0.09 | 0.08 | 0.08 | 0.02 | 0.03 | 0.03 | 0.01 | 0.05 | 2.12 |
| Debt / EBITDA | 0.19 | 0.19 | 0.30 | 0.97 | 0.86 | 0.17 | 0.41 | 0.13 | 0.03 | 0.09 | — |
| Net Debt / Equity | — | -0.14 | -0.01 | -0.03 | -0.12 | -0.27 | -0.14 | -0.13 | -0.23 | -0.59 | 0.42 |
| Net Debt / EBITDA | -0.34 | -0.34 | -0.04 | -0.37 | -1.40 | -1.98 | -2.27 | -0.57 | -0.68 | -1.01 | — |
| Debt / FCF | — | -0.37 | -0.04 | -0.43 | -1.39 | -1.77 | -1.51 | -0.42 | -0.78 | -1.17 | 0.18 |
| Interest Coverage | — | — | — | — | — | — | — | — | — | 19.25 | -1.12 |
Net cash position: cash ($482M) exceeds total debt ($173M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.56 | 3.56 | 3.63 | 3.34 | 4.99 | 5.43 | 7.06 | 7.08 | 8.50 | 4.21 | 1.74 |
| Quick Ratio | 3.50 | 3.50 | 3.58 | 3.30 | 4.89 | 5.35 | 6.96 | 6.99 | 8.41 | 4.15 | 1.73 |
| Cash Ratio | 2.61 | 2.61 | 2.75 | 2.52 | 4.03 | 4.35 | 5.90 | 5.97 | 6.57 | 3.37 | 1.55 |
| Asset Turnover | — | 0.82 | 0.74 | 0.62 | 0.52 | 0.55 | 0.46 | 0.51 | 0.60 | 0.69 | 0.32 |
| Inventory Turnover | 3.86 | 3.86 | 3.40 | 4.19 | 1.74 | 1.92 | 1.73 | 2.57 | 2.68 | 2.26 | 1.96 |
| Days Sales Outstanding | — | 45.14 | 44.67 | 47.35 | 48.66 | 71.90 | 59.46 | 44.91 | 69.58 | 65.50 | 77.11 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.0% | 6.4% | 5.2% | 2.7% | 3.5% | 3.9% | 1.7% | 5.8% | 11.2% | 1.6% | — |
| FCF Yield | 6.0% | 6.9% | 6.3% | 2.2% | 4.3% | 5.7% | 2.8% | 9.3% | 6.2% | 1.5% | 5.5% |
| Buyback Yield | 6.7% | 7.7% | 6.5% | 7.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | 0.1% |
| Total Shareholder Yield | 6.7% | 7.7% | 6.5% | 7.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | 0.1% |
| Shares Outstanding | — | $282M | $296M | $321M | $325M | $322M | $318M | $315M | $313M | $312M | $251M |
Generic entry litigation exposure
According to current market data, EXEL trades at a forward P/E of 15.55, which, when compared to the broader biotech sector, suggests that investors are applying a significant discount to account for the looming patent cliff and the inherent volatility of milestone-driven revenue streams.
The PEG ratio of 0.38 indicates that the market may be undervaluing the company's growth potential relative to its current earnings, likely due to skepticism regarding the long-term sustainability of the cabozantinib franchise. This valuation gap warrants further investigation into whether the market is overly pessimistic about the transition to the next-generation pipeline.
Based on reported financial statements, EXEL's ROIC has fluctuated between 1.0% and 10.1% over the last ten quarters, illustrating that the company's ability to compound capital is highly sensitive to the timing of R&D-heavy clinical trial cycles and the resulting impact on operating margins.
The variability in returns suggests that the company's capital allocation is currently optimized for pipeline expansion rather than consistent return maximization. Investors should monitor whether the shift toward ADC development can sustain higher ROIC levels as the company moves beyond its core tyrosine kinase inhibitor expertise.
As reported in recent SEC filings, EXEL's asset turnover remains low at 0.22, reflecting a business model that is heavily weighted toward intangible assets and R&D investment rather than physical capital, which limits the company's ability to drive rapid revenue growth through asset utilization alone.
The erratic nature of the cash conversion cycle, which swung from -84 days to 45 days, highlights the operational challenges of managing a commercial-stage biotech with lumpy milestone payments. This inefficiency appears structural, as the company prioritizes clinical development milestones over the optimization of its working capital cycle.
Based on the most recent quarterly data, EXEL maintains a current ratio of 3.26, providing a substantial liquidity cushion that appears more than adequate to navigate potential legal setbacks or delays in the commercialization of its next-generation oncology pipeline assets.
This strong liquidity position suggests that the company is well-insulated from short-term financing risks, allowing management to maintain its aggressive R&D spending despite the ongoing Hatch-Waxman litigation. The high quick ratio further confirms that the company's liquidity is not overly dependent on inventory liquidation, which is favorable given the specialized nature of its products.
The P/E ratio is frequently misapplied to EXEL, as it obscures the impact of lumpy, non-recurring milestone payments that artificially inflate or deflate earnings, thereby providing a distorted view of the company's underlying operational profitability and its true cash-generating capacity.
Analysts should instead focus on EV/EBITDA or P/FCF, which better account for the company's capital structure and the significant cash outflows associated with R&D. Relying on P/E in this context may lead to erroneous conclusions about the company's valuation, as it fails to normalize for the volatility inherent in the biotech business model.
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EXEL stock.
Exelixis, Inc.'s current P/E ratio is 20.0x. The historical average is 28.0x. This places it at the 50th percentile of its historical range.
Exelixis, Inc.'s current EV/EBITDA is 15.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 24.9x.
Exelixis, Inc.'s return on equity (ROE) is 35.5%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -31.9%.
Based on historical data, Exelixis, Inc. is trading at a P/E of 20.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Exelixis, Inc. has 96.4% gross margin and 37.6% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Exelixis, Inc.'s Debt/EBITDA ratio is 0.2x, indicating low leverage. A ratio below 2x is generally considered financially healthy.